ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
AstraZeneca’s Lumoxiti secures FDA nod to treat hairy cell leukaemia
pharmaceutical-technology
September 21, 2018AstraZeneca and its research and development arm MedImmune have obtained approval from the US Food and Drug Administration (FDA) for the use of Lumoxiti to treat adults with relapsed or refractory hairy cell leukaemia. -
FDA Approves New Kind of Treatment for Hairy Cell Leukemia
americanpharmaceuticalreview
September 18, 2018The U.S. Food and Drug Administration (FDA) approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients... -
FDA Approves Lumoxiti
drugs
September 14, 2018The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemi
Pharma Sources Insight January 2025
